PE20070378A1 - FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA - Google Patents

FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA

Info

Publication number
PE20070378A1
PE20070378A1 PE2006000998A PE2006000998A PE20070378A1 PE 20070378 A1 PE20070378 A1 PE 20070378A1 PE 2006000998 A PE2006000998 A PE 2006000998A PE 2006000998 A PE2006000998 A PE 2006000998A PE 20070378 A1 PE20070378 A1 PE 20070378A1
Authority
PE
Peru
Prior art keywords
cyclodextrin
factor
beta
inhibitor
formulation
Prior art date
Application number
PE2006000998A
Other languages
English (en)
Inventor
Munir N Nassar
Uday S Gogate
Timothy M Malloy
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20070378A1 publication Critical patent/PE20070378A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

REFERIDA A UNA FORMULACION FARMACEUTICA INYECTABLE QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa Y UN AGENTE DE SOLUBILIZACION TAL COMO UNA BETA-CICLODEXTRINA SUSTITUIDA, DONDE EL INHIBIDOR DEL FACTOR Xa ES UN COMPUESTO PIRAZOLOPIRIDINA SUSTITUIDO CON R3, R4 Y R5, DONDE R3 ES H2N(C=O)-, ALQUIL-SO2-, ENTRE OTROS; R4 ES ALCOXI Y HALOGENO; R5 ES UN HETEROCICLO DONDE Q ES UN ANILLO MONOCICLICO DE 6 MIEMBROS EN DONDE 0, 1 O2 ENLACES DOBLES ESTAN PRESENTES DENTRO DEL ANILLO Y EL ANILLO SE SUSTITUYE CON 0, 1 O 2 GRUPOS R5a QUE SE SELECCIONA DE H, O O ALQUILO Y Q1 ES C=O. ASIMISMO, LA FORMULACION PUEDE COMPRENDER UN AMORTIGUADOR TAL COMO ACIDO TARTARICO, ACIDO CITRICO, ACIDO CLORHIDRICO, ENTRE OTROS. EL INHIBIDOR DEL FACTOR Xa SE SELECCIONA DE APIXABAN O RAZAXABAN Y LA BETA-CICLODEXTRINA SUSTITUIDA SE SELECCIONA DE SULFOBUTIL ETER BETA-CICLODEXTRINA (SBE-CD) O HIDROXIPROPIL BETA-CICLODEXTRINA (HPB-CD). DICHA FORMULACION ES UTIL PARA PREVENIR O TRATAR TROMBOSIS VENOSA, TROMBOSIS DE VENA PROFUNDA Y SINDROME CORORNARIO AGUDO
PE2006000998A 2005-08-17 2006-08-17 FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA PE20070378A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70907705P 2005-08-17 2005-08-17
US11/464,519 US20070191306A1 (en) 2005-08-17 2006-08-15 FACTOR Xa INHIBITOR FORMULATION AND METHOD

Publications (1)

Publication Number Publication Date
PE20070378A1 true PE20070378A1 (es) 2007-05-04

Family

ID=37654897

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000998A PE20070378A1 (es) 2005-08-17 2006-08-17 FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA

Country Status (10)

Country Link
US (2) US20070191306A1 (es)
EP (1) EP1924291A2 (es)
JP (1) JP2009504746A (es)
AR (1) AR055377A1 (es)
BR (1) BRPI0614827A2 (es)
CA (1) CA2619214A1 (es)
MX (1) MX2008002057A (es)
PE (1) PE20070378A1 (es)
TW (1) TW200800270A (es)
WO (1) WO2007022165A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3106463T6 (da) 2008-10-22 2020-02-24 Array Biopharma Inc Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer
RU2012101214A (ru) * 2009-06-16 2013-07-27 Пфайзер Инк. Лекарственные формы апиксабана
EP3251660B1 (en) 2010-02-25 2019-10-16 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban formulations
SG11201408511QA (en) * 2012-06-27 2015-01-29 Takeda Pharmaceutical Liquid preparations of amines and organic acids stabilized by salts
SG10201702048VA (en) * 2012-09-26 2017-04-27 Bristol Myers Squibb Holdings Ireland Apixaban liquid formulations
CN104650072B (zh) * 2013-11-18 2016-03-16 成都苑东生物制药股份有限公司 一种吡啶类衍生物
PE20181888A1 (es) * 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CN115715770B (zh) * 2021-08-24 2024-01-26 新领医药技术(深圳)有限公司 阿哌沙班透皮贴剂及其制备方法
NL2029536B1 (en) 2021-10-27 2023-05-26 Pharma Data S A Apixaban suspension and preparation method
WO2023072967A1 (en) 2021-10-27 2023-05-04 Pharma-Data S.A. Apixaban suspension and preparation method

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4745105A (en) * 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
JP2003509409A (ja) * 1999-09-13 2003-03-11 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド アザシクロアルカノンセリンプロテアーゼ阻害剤
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2726702A1 (en) * 2001-09-21 2003-04-03 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors

Also Published As

Publication number Publication date
AR055377A1 (es) 2007-08-22
JP2009504746A (ja) 2009-02-05
CA2619214A1 (en) 2007-02-22
BRPI0614827A2 (pt) 2011-04-19
MX2008002057A (es) 2008-04-16
WO2007022165A2 (en) 2007-02-22
US20070191306A1 (en) 2007-08-16
TW200800270A (en) 2008-01-01
EP1924291A2 (en) 2008-05-28
US20090291913A1 (en) 2009-11-26
WO2007022165A3 (en) 2007-08-23
WO2007022165B1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
PE20070378A1 (es) FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA
PE20190624A1 (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2
CR8047A (es) Procedimiento de tratamiento de la arterosclerosis, dislipidemias y afecciones relacionadas y composiciones farmaceuticas
GT200000219A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
BRPI0713132B8 (pt) compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
PE20071136A1 (es) Derivados de anilina sustituida como antagonistas de la histamina h3
DOP2003000566A (es) Cicloalcanindoles con sustitución con fluor, composiciones que contienen estos compuestos y metodos de preparación para un medicamento
ATE378332T1 (de) Benzofuranderivate,verfahren zu deren herstellung und zwischenprodukte davon
ECSP088239A (es) Composición de liberación de fármaco sostenida
PE20061153A1 (es) Compuestos heterociclicos como inhibidores del factor viia
PE20061015A1 (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
AR037755A1 (es) Composiciones acuosas con contenido de metronidazol
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
AR066962A1 (es) Compuesto heterociclico fusionado
UY28917A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas composiciones farmaceuticas y su uso terapeutico
AR022909A1 (es) Sinergia entre heparina de bajo peso molecular e inhibidores de la agregacion plaquetaria, que provee una terapia combinada para la prevencion ytratamiento de diversas afecciones tromboembolicas
EA201990501A1 (ru) Фармацевтическая композиция
NI201400122A (es) Agentes terapéuticos para administración subcutánea optimizados
GEP20247585B (en) Furoindazole derivatives
HN2003000162A (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
PE20160842A1 (es) Piperidiniltetrahidroquinolinas sustituidas
MX2022007670A (es) Compuestos antihelminticos que comprenden una estructura de quinolina.

Legal Events

Date Code Title Description
FC Refusal